Nanocarriers surface engineered with cell membranes for cancer targeted chemotherapy

Purpose: Conventional chemotherapy suffers from poor targeting and severe side effects, while synthetic nanocarriers are often cleared by the immune system and lack precise tumor targeting. Cell membrane-coated nanocarriers (CMCNs) offer a biomimetic strategy to improve biocompatibility, immune evasion, circulation time, and homotypic tumor targeting.

Hypothesis: No formal experimental hypothesis. Central thesis: coating nanocarriers with natural cell membranes transfers parent-cell functions—such as immune evasion, prolonged circulation, and homotypic or injury-site targeting—thereby improving cancer-targeted chemotherapy and reducing off-target toxicity.

Aims: Describe manufacturing processes for CMCNs, including membrane extraction, core preparation, and fusion. - Review therapeutic applications of different cell membrane-coated nanocarrier systems. - Discuss advantages, obstacles, and future prospects for clinical translation.

Delivery system: Nanocarrier cores: organic (PLGA, liposomes, gelatin, perfluorocarbon) and inorganic (iron oxide, gold, mesoporous silica, upconversion nanoparticles, MOFs). - Cell membranes: red blood cells (RBCs), white blood cells (neutrophils, macrophages), platelets, cancer cells, T cells, dendritic cells, and hybrid membranes. - Payloads: chemotherapeutics (doxorubicin, paclitaxel, dicarbazine, celastrol, hederagenin), photothermal/photodynamic agents (melanin, black phosphorus quantum dots, gold nanocages, IR780, chlorin e6), siRNA, oxygen, cytokines, imaging agents. - Targeting mechanisms: passive EPR effect, homotypic targeting, ligand/receptor recognition, immune evasion, and injury-site adhesion. - Surface modifications: folate, RGD, NGR, CDX, AS1411 aptamer, hyaluronidase, PEG, cholesterol, proteins.

Approach: Review of in vitro and in vivo studies. Preclinical models include mice and rabbits, with cell lines such as HeLa, HepG2, UM-SCC-7, COS7, MDA-MB-231, MCF7, A549, U87MG-Luc, 4T1, EL4, and RAW264.7. Disease contexts include breast cancer, lung metastasis, glioma, hepatocellular carcinoma, pancreatic cancer, melanoma, and others. Most systems remain preclinical.

Key methods: Membrane extraction: hypotonic lysis, centrifugation, sucrose gradient, freeze-thaw. - Fusion: sonication, membrane extrusion, microfluidic electroporation. - Characterization: TEM, DLS, Western blot, SDS-PAGE, flow cytometry, lipid assays. - In vitro: MTT, apoptosis, cellular uptake, immune evasion, T-cell activation. - In vivo: tumor volume, survival, biodistribution, IVIS, MRI, CT, histology.

Key results: RBC membrane-coated PLGA nanocarriers improved blood retention to 72 hours vs 15.8 hours for typical PEGylated stealth nanocarriers. - Neutrophil membrane-coated nanocarriers showed 2–3-fold higher accumulation in metastatic foci than PLGA-PEG and bare nanocarriers. - T lymphocyte membrane-coated nanocarriers achieved a 2-fold increase in particle density throughout tumors in mice. - RBC-platelet hybrid membrane-coated PLGA nanocarriers had longer circulation and better binding to MDA-MB-231 breast cancer cells. - Macrophage-cancer hybrid membrane-coated DOX-loaded PLGA nanocarriers reduced lung metastatic nodules by ~88.9% in a breast cancer metastasis model. - Platelet membrane-coated black phosphorus quantum dots carrying hederagenin showed stronger fluorescence and higher retention at cancer sites after 48 h. - Cancer cell membrane-coated iron oxide nanocarriers demonstrated homotypic self-targeting and inhibited homologous tumor growth in vivo. - IL-2-loaded PLGA nanocarriers wrapped in dendritic cell membranes sustained strong T-cell responses. - CAR-T cell membrane-coated mesoporous silica nanoparticles targeted GPC3-expressing hepatocellular carcinoma cells in vitro and in vivo.

Interpretation: CMCNs merge material science and biomimicry, offering biocompatibility, immune evasion, homotypic targeting, prolonged circulation, and reduced drug resistance. The authors conclude that CMCNs are a promising platform for cancer-targeted chemotherapy, but standardized manufacturing and quality control are needed for clinical translation.

Limitations: Review article; no primary data. - Cell membrane yield is low and large-scale production is expensive. - Extraction and purification protocols are not standardized across laboratories. - Protein loss during membrane isolation can reduce targeting and functionality. - Allogeneic membranes may raise immunogenicity and blood-type compatibility concerns. - Drug loading and controlled release remain challenging, especially for platelet membranes. - Cancer cell membrane use risks residual genetic material. - In vivo transport mechanisms of CMCNs are incompletely understood. - Regulatory, quality control, and scale-up hurdles remain before clinical translation.